跳至主要内容
临床试验/NCT00335218
NCT00335218已完成4 期

A Multi-center, Prospective, Randomized, Double-blind, Placebo-controlled, Two-arm, Phase IV Study to Investigate the Influence of a Continuous Combined Estrogen-progestin Regimen Containing 2 mg Estradiol Valerate and 2 mg Dienogest (Climodien® / Lafamme®) on the Fat Distribution in Otherwise Healthy Early Postmenopausal Women

Bayer0 个研究点目标入组 67 人开始时间: 2002年7月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
Bayer
入组人数
67
主要终点
Individual relative change of abdominal visceral fat measured by magnetic resonance imaging

研究概览

简要总结

The aim of this study is to explore the effects of hormone replacement therapy with EV/DNG on abdominal fat distribution measured by magnetic resonance imaging.

详细描述

The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been renamed to Bayer Schering Pharma AG, Germany.Bayer Schering Pharma AG, Germany is the sponsor of the trial.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Participant, Investigator, Outcomes Assessor)

入排标准

年龄范围
48 Years 至 60 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • Healthy early postmenopausal women
  • BMI between 25 and 30

排除标准

  • Contra-indication(s) for hormone treatment
  • Metabolic diseases
  • Concomitant medication with influence on lipid metabolism

研究组 & 干预措施

Arm 1

Experimental

干预措施: Climodien / Lafamme (BAY86-5027) (Drug)

Arm 2

Placebo Comparator

干预措施: Placebo (Drug)

结局指标

主要结局

Individual relative change of abdominal visceral fat measured by magnetic resonance imaging

时间窗: Baseline and after 24 weeks of treatment

次要结局

  • Adverse events collection(During whole study period)
  • Parameters of body composition and lipid metabolism(Baseline and after 24 weeks of treatment)

研究者

发起方
Bayer
申办方类型
Industry
责任方
Sponsor

相似试验